eligibility_summary
Adults (≥18) with CD7+ relapsed/refractory T‑NHL or AML. Cohort A: specified T‑NHL subtypes, ≥2 prior lines (T‑PLL ≥1), ALCL requires prior brentuximab, or relapse post auto/allo HCT. Cohort B: AML/ambiguous lineage per R/R rules, FLT3/IDH+ must be refractory/intolerant to targeted agents, blasts <30k. Need ECOG ≤2, adequate organs (and counts if T‑NHL without marrow), contraception, consent, no effective SOC, donor pre‑ID for dose‑escalation. Exclude: recent therapy, T‑cell‑lytic Ab <8 wk, prior anti‑CD7, disqualifying post‑alloHCT/GVHD/immunosuppression, HBV/HCV/HIV, pregnancy/breastfeeding, serious infection/comorbidity, uncontrolled hypotension.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: WU-CART-007, a biological, gene-edited allogeneic anti-CD7 CAR T-cell therapy. Mechanism of action: CAR specifically binds CD7 to activate T-cell cytotoxicity, engineered CD7 knockout prevents fratricide among CAR T cells, TRAC (T-cell receptor alpha constant) knockout ablates endogenous TCR signaling to reduce graft-versus-host disease, restricting recognition to CD7 via the CAR. Target cells/pathways: CD7 antigen on malignant T/NK lineage cells (T-cell NHL subtypes, NK/T-cell lymphoma) and aberrantly on ~30% of AML blasts, expected on-target depletion of normal CD7+ T/NK cells (lymphodepletion). Effector pathways include CAR-driven activation with perforin/granzyme cytotoxicity and cytokine release, endogenous TCR pathway disabled. Phase 1 dose-escalation/expansion with lymphodepleting chemotherapy pre-infusion.